Epilepsy care may need to move beyond a single seizure focus
Epilepsy is increasingly being understood as a disorder of distributed brain networks rather than a condition driven by one isolated seizure source. That shift matters in the operating room and at the bedside, where a seizure onset zone can look deceptively clear even when seizures persist after resection. A new framework from investigators in Frontiers in Network Physiology proposes that clinicians may need to map not only where seizures begin, but also how strongly surrounding brain regions can be recruited into the epileptic circuit.
The idea is straightforward but clinically disruptive. If epileptic activity depends on a broader set of interconnected structures, then a resection strategy based only on the visible onset zone may leave part of the pathological network behind. Persistent postoperative seizures fit that pattern. So do cases in which neuromodulation helps, but does not fully suppress events, because the wrong nodes were targeted or the network remained too excitable elsewhere.
Two dimensions define the epileptic network model
The proposed framework divides epileptic networks into two complementary features: local excitability and network recruitment. Local excitability describes how readily a brain region generates or amplifies epileptiform activity. Network recruitment captures how effectively that activity spreads to connected structures and engages a wider circuit.
This distinction creates a more functional map than a purely anatomical one. A region may be highly excitable without becoming a major distributor of seizures. Another area may not be the initial trigger but may still serve as a powerful amplifier or relay point. Surgical planning based only on the seizure onset zone can miss those roles, especially in complex focal epilepsy, where the visible electrographic onset is only part of the biology.
The review argues that individualized epilepsy treatment will improve if these two dimensions can be measured directly rather than inferred indirectly from seizure appearance alone. That approach would allow clinicians to identify which structures are most likely to initiate seizures, which are most likely to sustain them, and which may be better targets for stimulation than for resection.
Aperiodic slope and polyspikes point to different network properties
The article focuses on two electrophysiologic signatures that may help construct these maps. The first is the aperiodic, or 1/f, slope of field-potential recordings. In this framework, the aperiodic slope is presented as a mechanistically grounded marker of local excitability. The second is polyspike structure, which may reflect how strongly epileptiform activity spreads across distributed network nodes.
These measures are not redundant. The 1/f slope is tied to local tissue dynamics and excitability, while polyspikes may be a visible signature of broader recruitment. Together, they provide a way to separate a region that is electrically unstable from one that is actively participating in a larger epileptic circuit.
That separation matters because current intracranial recordings often capture complex discharges without clarifying whether the source region alone explains the event. A field-potential trace can reveal abnormal activity, but not every abnormality carries the same surgical or therapeutic weight. A biomarker that captures excitability and another that captures recruitment may offer a more faithful description of network behavior.
Experimental data support a translational biomarker strategy
The authors point to recent studies and preliminary data combining electrophysiology, calcium imaging, and computational modeling. Those complementary methods suggest that the two proposed biomarkers track related but distinct features of epileptic network function. Electrophysiology can capture electrical signatures in tissue, calcium imaging can show cell-level activation patterns, and computational modeling can test how such signals propagate through networks.
Across those approaches, the signal is consistent: epileptic tissue is not simply “on” or “off.” Some nodes are unusually excitable. Others are disproportionately effective at spreading activity. Still others may appear important only when viewed within the context of the wider network. A biomarker system built on that distinction could help explain why two patients with similar seizure semiology may respond very differently to the same procedure.
The practical implication is a move toward network excitability mapping. Instead of relying on a single anatomical target, clinicians could eventually build individualized maps that identify which regions are biologically primed for seizure generation and which regions recruit the rest of the network. Such maps could be especially useful when standard localization is ambiguous or when seizures persist after a technically successful intervention.
Surgical planning and neuromodulation could both change
The framework has direct implications for epilepsy surgery and device-based therapy. In surgical planning, a map of local excitability and network recruitment could refine the choice of tissue to remove or spare. In neuromodulation, it could help determine which nodes should be stimulated to disrupt network propagation rather than simply suppress the most obvious electrographic focus.
This is especially relevant in patients whose seizures continue after apparently adequate resection. In those cases, residual epileptogenic tissue may not be confined to the removed focus. A broader network may still be capable of generating or sustaining seizures, which would explain the incomplete response. A biomarker that identifies those nodes before treatment could improve patient selection and intervention design.
The authors also frame these measures as translational, not merely descriptive. Their goal is not only to classify abnormal activity but to create biomarkers that can travel from experimental systems into human care. That requires linking tissue-level physiology to clinically meaningful decisions, including whether to cut, ablate, stimulate, or observe.
The next step is proving clinical utility
The framework is promising, but it still needs prospective validation in patients. The central question is whether excitability and recruitment markers can improve seizure localization, predict postoperative outcome, or guide neuromodulation more effectively than conventional paradigms. Without that step, the model remains biologically compelling but clinically unproven.
Standardized methods will also matter. A biomarker that depends on recording conditions, signal processing choices, or task-specific model assumptions will be difficult to deploy across centers. For network excitability mapping to influence routine epilepsy care, the field will need reproducible acquisition and analysis standards, plus evidence that the markers change management in ways that improve seizure control.
For now, the study offers a sharper way to think about epileptic tissue. Seizures may begin in one place, but they are often sustained by a network. If excitability and recruitment can be measured separately and mapped reliably, epilepsy treatment could become more precise than a search for a single focus ever allowed.